2008
Correspondence of Interactive Voice Response (IVR) Reports of Nicotine Withdrawal, Craving, and Negative Mood with Questionnaire Ratings
Toll BA, Cooney JL, McKee SA, O'Malley SS, Cooney NL. Correspondence of Interactive Voice Response (IVR) Reports of Nicotine Withdrawal, Craving, and Negative Mood with Questionnaire Ratings. Nicotine & Tobacco Research 2008, 10: 1057-1064. PMID: 18584469, PMCID: PMC2791461, DOI: 10.1080/14622200802097498.Peer-Reviewed Original ResearchConceptsNicotine withdrawalDepressive symptomsSmoking cessation trialCessation trialDaily smokersInteractive voice response systemVoice response systemDaily assessmentCravingWeeksNegative moodWithdrawalSymptomsPaper questionnaireQuestionnaire ratingsReportFuture studiesQuestionnaireIVR systemMoodDaysSample sizeDaily reportsSmokersSmoking
2006
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
O’Malley S, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. JAMA Internal Medicine 2006, 166: 667-674. PMID: 16567607, DOI: 10.1001/archinte.166.6.667.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAmbulatory CareDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLinear ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsNicotineNicotinic AgonistsSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTreatment OutcomeWeight GainConceptsNicotine patch therapyNicotine patchPatch therapyDouble-blind placebo-controlled trialHigher continuous abstinence ratesLow-dose naltrexone therapyNaltrexone hydrochlorideWeight gainTreatment completersOral naltrexone hydrochlorideOutpatient research centerWeight-concerned smokersContinuous abstinence ratesPlacebo-controlled trialPrimary end pointSecond-line treatmentNicotine replacement therapyNaltrexone augmentationNaltrexone therapyPlacebo groupQuit dateTreat analysisAbstinence ratesReplacement therapySmoking cessation
2003
Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers
Cooney JL, Cooney NL, Pilkey DT, Kranzler HR, Oncken CA. Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers. Addiction 2003, 98: 913-921. PMID: 12814497, DOI: 10.1046/j.1360-0443.2003.00337.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismBreath TestsCarbon MonoxideCotinineCuesFemaleHumansImagery, PsychotherapyMaleMiddle AgedMotivationNicotineNicotinic AgonistsSalivationSmokingSubstance Withdrawal SyndromeConceptsNicotine deprivationSmoking urgesSelf-reported urgeAcute nicotine deprivationNon-deprived stateDay treatment programAlcohol-dependent smokersNeutral cuesMood inductionCue presentationCue exposureSubjects designTreatment programLaboratory sessionsUrgeRisk of relapseSessionsAlcoholic smokersSmoking cessationHeavy smokersAlcoholic patientsAcute effectsEarly recoverySmokersCues
1999
CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving?
Petrakis I, Trevisan L, D'Souza C, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal J. CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving? Alcohol Clinical And Experimental Research 1999, 23: 1336-1341. PMID: 10470976, DOI: 10.1111/j.1530-0277.1999.tb04355.x.Peer-Reviewed Original ResearchConceptsAlcohol-dependent patientsHealthy controlsEndorphin levelsCSF levelsMonoamine metabolitesCSF measuresHealthy subjectsNorepinephrine metabolite MHPGLower CSF levelsBeta-endorphin levelsEarly-onset patientsCerebrospinal fluid levelsLate-onset patientsCentral neurotransmitter systemsCSF monoamine metabolitesDopamine metabolite HVAAlcohol cue exposureAlcohol-dependent individualsCue-Induced CravingAlcohol cue reactivityLumbar punctureMetabolite HVANeurotransmitter systemsMonoaminergic dysregulationMetabolite MHPG